No evidence of fluctuations in daily step count between infusions in people with multiple sclerosis treated with anti-CD20 monoclonal antibodies
This study found no evidence of an association between timing of anti-CD20 infusion and changes in STEPS. Findings highlight the need for integrating objective measures with patient-reported outcomes and biomarkers in future research to better understand potential treatment fluctuations.
Authors
- Gabby B. Joseph (ORCID: https://orcid.org/0000-0002-7736-123X)
- Bruce Cree (ORCID: https://orcid.org/0000-0001-7689-2533)
- Valerie J. Block (ORCID: https://orcid.org/0000-0001-6199-5484)
- Jeffrey Marc Gelfand (ORCID: https://orcid.org/0000-0002-5121-3319)
- Shane T. Poole (ORCID: https://orcid.org/0000-0002-3203-151X)
- Riley M. Bove (ORCID: https://orcid.org/0000-0002-2034-8800)
- Kyra Henderson (ORCID: https://orcid.org/0009-0006-8350-0474)
Institutions
- University of California, San Francisco (US)
Publication Details
- Journal
- Multiple Sclerosis Journal - Experimental Translational and Clinical
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1177/20552173251329817
- Primary Topic
- Multiple Sclerosis Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Multiple Sclerosis Society
- Multiple Sclerosis Society
- NIH Clinical Center